Day One Biopharmaceuticals (DAWN) Competitors $6.79 -0.40 (-5.56%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.80 +0.00 (+0.07%) As of 07/11/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. HCM, AMRX, CPRX, BHC, OGN, XENE, MIRM, IBRX, GMTX, and ARWRShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), Organon & Co. (OGN), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), ImmunityBio (IBRX), Gemini Therapeutics (GMTX), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Its Competitors HUTCHMED Amneal Pharmaceuticals Catalyst Pharmaceuticals Bausch Health Cos Organon & Co. Xenon Pharmaceuticals Mirum Pharmaceuticals ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Day One Biopharmaceuticals (NASDAQ:DAWN) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Does the media favor DAWN or HCM? In the previous week, Day One Biopharmaceuticals had 1 more articles in the media than HUTCHMED. MarketBeat recorded 3 mentions for Day One Biopharmaceuticals and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.47 beat Day One Biopharmaceuticals' score of 0.63 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is DAWN or HCM more profitable? HUTCHMED has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -42.66%. HUTCHMED's return on equity of 0.00% beat Day One Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Day One Biopharmaceuticals-42.66% -14.98% -13.04% HUTCHMED N/A N/A N/A Do analysts recommend DAWN or HCM? Day One Biopharmaceuticals currently has a consensus price target of $29.00, indicating a potential upside of 327.10%. HUTCHMED has a consensus price target of $19.00, indicating a potential upside of 18.45%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Day One Biopharmaceuticals is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable earnings and valuation, DAWN or HCM? HUTCHMED has higher revenue and earnings than Day One Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$131.16M5.25-$95.50M-$0.71-9.56HUTCHMED$630.20M4.44$37.73MN/AN/A Do insiders and institutionals have more ownership in DAWN or HCM? 88.0% of Day One Biopharmaceuticals shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 6.2% of Day One Biopharmaceuticals shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, DAWN or HCM? Day One Biopharmaceuticals has a beta of -1.27, meaning that its share price is 227% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. SummaryDay One Biopharmaceuticals beats HUTCHMED on 8 of the 15 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$688.25M$2.94B$5.56B$9.10BDividend YieldN/A2.41%5.06%4.02%P/E Ratio-9.5620.8528.2620.26Price / Sales5.25262.20427.10161.28Price / CashN/A42.1137.1257.67Price / Book1.367.638.045.49Net Income-$95.50M-$55.05M$3.19B$250.45M7 Day Performance-0.15%8.43%3.62%4.79%1 Month Performance1.80%8.14%5.98%9.59%1 Year Performance-55.36%1.62%29.39%16.41% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals2.5195 of 5 stars$6.79-5.6%$29.00+327.1%-55.4%$688.25M$131.16M-9.5660News CoverageHCMHUTCHMED1.6191 of 5 stars$15.42-2.5%$19.00+23.2%-17.3%$2.76B$630.20M0.001,811Gap DownAMRXAmneal Pharmaceuticals2.8528 of 5 stars$8.41-0.1%$11.60+37.9%+15.9%$2.64B$2.79B-210.208,100CPRXCatalyst Pharmaceuticals4.9355 of 5 stars$20.95-2.4%$32.83+56.7%+31.5%$2.62B$491.73M13.3480BHCBausch Health Cos3.8348 of 5 stars$6.88-2.5%$7.42+7.8%-13.3%$2.61B$9.63B-62.5520,700OGNOrganon & Co.4.8432 of 5 stars$9.74-2.2%$18.00+84.8%-53.4%$2.59B$6.40B3.384,000Trending NewsXENEXenon Pharmaceuticals3.4496 of 5 stars$31.83-4.3%$54.82+72.2%-25.0%$2.55B$9.43M-9.85210News CoverageOptions VolumeMIRMMirum Pharmaceuticals2.8556 of 5 stars$50.47+0.3%$65.50+29.8%+33.5%$2.49B$336.89M-31.35140News CoverageAnalyst ForecastIBRXImmunityBio2.3668 of 5 stars$2.72flat$12.25+350.4%-57.6%$2.40B$14.74M-4.69590News CoverageAnalyst ForecastGMTXGemini TherapeuticsN/A$54.75+3.0%N/A+21.3%$2.37BN/A-54.7530ARWRArrowhead Pharmaceuticals3.5849 of 5 stars$16.84+0.3%$43.71+159.6%-34.9%$2.32B$3.55M-12.03400Gap Down Related Companies and Tools Related Companies HUTCHMED Competitors Amneal Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors Bausch Health Cos Competitors Organon & Co. Competitors Xenon Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors ImmunityBio Competitors Gemini Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
